Biogen scraps controversial Alzheimer’s drug Aduhelm

Biogen takes $60 million quarterly hit in opting to no longer study or sell the drug that never met expectations.

You may also be interested in

September 20, 2024

September 20, 2024

1501 State St.
East St Louis, IL 62205
(618) 271-0468

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec.

Get our Weekly recap with the latest news, articles and resources.

Cookie policy

We use our own and third party cookies to allow us to understand how the site is used and to support our marketing campaigns.